Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
Oncology · 2025
DOI: 10.1159/000546515 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Oncology, 2025. Verfasst von Takanori Suzuki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Bevacizumab, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized.
Abstract (Originalsprache)
Introduction
Atezolizumab plus bevacizumab (ATZ+BV) is used for the treatment of Barcelona Clinic Liver Cancer (BCLC) stage B unresectable hepatocellular carcinoma (u-HCC) patients. However, the efficacy of ATZ+BV in various BCLC stage B conditions, especially the up-to-seven criteria in/out, has not been fully investigated.
Methods
We enrolled 83 BCLC stage B u-HCC patients with Child-Pugh class A who were treated with ATZ+BV as the first-line systemic chemotherapy in the study. All patients were evaluated for initial responses by dynamic computed tomography or magnetic resonance imaging after the initiation of ATZ+BV, and therapeutic efficacy was assessed.
Results
When stratified by up-to-seven criteria, progression-free survival (PFS) was significantly prolonged in patients with up-to-seven in (in vs. out: median 21.0 vs. 8.2 months, P = 0.006), and the Cox proportional hazard model showed that up-to-seven out/in was the significant factor contributing to PFS (out vs. in: HR 2.58, P = 0.007). We next evaluated PFS stratified by the maximum intrahepatic tumor diameter and number of intrahepatic tumors, which constitute the up-to-seven criteria. The number of tumors was a significant factor contributing to PFS (> 7 vs. ≤ 7: HR 1.75, P = 0.040), but maximum tumor size was not (> 5 cm vs. ≤ 5 cm: HR 1.19, P = 0.588).
Conclusions
In BCLC stage B u-HCC patients treated with ATZ+BV, a high number of intrahepatic tumors was associated with poor PFS. Therefore, it may be better to consider additional treatment strategies in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, matsuura@med.nagoya-cu.ac.jp.
- Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
- Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan.
- Department of Gastroenterology, Kasugai Municipal Hospital, Kasugai, Japan.
- Department of Gastroenterology, Chukyo Hospital, Nagoya, Japan.
Zitieren
APA
Suzuki, T., Matsuura, K., Kato, D., Hayashi, K., Okayama, K., Okumura, F., Sobue, S., Kusakabe, A., Hasegawa, I., Narita, K., Mizoshita, T., Kimura, Y., Sato, R., Kondo, H., Ozasa, A., Kawamura, H., Fujiwara, K., Nojiri, S., & Kataoka, H. (2025). Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis. Oncology. https://doi.org/10.1159/000546515
Vancouver
Suzuki T, Matsuura K, Kato D, Hayashi K, Okayama K, Okumura F, et al. Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis. Oncology. 2025. doi:10.1159/000546515
BibTeX
@article{Suzuki2025,
author = {Suzuki, Takanori and Matsuura, Kentaro and Kato, Daisuke and Hayashi, Katsumi and Okayama, Kohei and Okumura, Fumihiro and Sobue, Satoshi and Kusakabe, Atsunori and Hasegawa, Izumi and Narita, Kiyoto and Mizoshita, Tsutomu and Kimura, Yoshihide and Sato, Ryo and Kondo, Hiromu and Ozasa, Atsushi and Kawamura, Hayato and Fujiwara, Kei and Nojiri, Shunsuke and Kataoka, Hiromi},
title = {Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis},
journal = {Oncology},
year = {2025},
doi = {10.1159/000546515}
}
EUVIMED